Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

Rugo Hope S.; Turner Nicholas C.; Finn Richard S.; Joy Anil A.; Verma Sunil; Harbeck Nadia; Masuda Norikazu; Im Seock-Ah; Huang Xin; Kim Sindy; Sun Wan; Iyer Shrividya; Schnell Patrick; Bartlett Cynthia Huang; Johnston Stephen

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

【24h】

Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

机译：Palbociclib加上高龄妇女的内分泌治疗，具有人力资源+ / Her2晚期乳腺癌：对随机腭临床研究的汇总分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: Because incidence of breast cancer and comorbidities increase with age, it is important to determine treatment benefit in elderly patients. We evaluated outcomes with palbociclib plus endocrine therapy in patients aged = 65 years.

机译：目的：因为乳腺癌和合并症随年龄增加的发生率，因此确定老年患者治疗益处是重要的。我们评估了帕尔巴昔米利布加内分泌治疗的结果，≥65岁。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共11页
作者
Rugo Hope S.; Turner Nicholas C.; Finn Richard S.; Joy Anil A.; Verma Sunil; Harbeck Nadia; Masuda Norikazu; Im Seock-Ah; Huang Xin; Kim Sindy; Sun Wan; Iyer Shrividya; Schnell Patrick; Bartlett Cynthia Huang; Johnston Stephen;
展开▼
作者单位

Univ Calif San Francisco Helen Diller Family Comprehens Canc Ctr 1600 Divisidero St 2nd Floor;

Inst Canc Res Fulham Rd London SW3 6JJ England;

Univ Calif Los Angeles David Geffen Sch Med 2825 Santa Monica Blvd Suite 200 Santa Monica CA;

Cross Canc Inst 11560 Univ Ave NW Edmonton AB T6G 1Z2 Canada;

Univ Calgary 1403-29 St NW Calgary AB Canada;

Univ Munich LMU Breast Ctr Marchioninistr 15 D-81377 Munich Germany;

Natl Hosp Org Osaka Natl Hosp Chuo Ku 2 Chome 1-14 Hoenzaka Osaka Osaka 5400006 Japan;

Seoul Natl Univ Coll Med Canc Res Inst Seoul Natl Univ Hosp 101 Daehak Ro Seoul 03080 South;

Pfizer Inc 10646 Sci Ctr Dr San Diego CA 92121 USA;

Pfizer Inc 10646 Sci Ctr Dr San Diego CA 92121 USA;

Pfizer Inc 10646 Sci Ctr Dr San Diego CA 92121 USA;

Pfizer Inc 235 E 42nd St New York NY 10017 USA;

Pfizer Inc 235 E 42nd St New York NY 10017 USA;

Pfizer Inc 500 Arcola Rd Collegeville PA 19426 USA;

Inst Canc Res Fulham Rd London SW3 6JJ England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Advanced breast cancer; Age; HR-positive; Endocrine treatment; HER2-negative; Tumour; Letrozole; Fulvestrant; Palbociclib;

机译：先进的乳腺癌;年龄;hr阳性;内分泌治疗;her2-dange;肿瘤;letrozole;ultvastrant;palbociclib;

相似文献

外文文献
中文文献
专利

1. Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies [J] . Rugo Hope S., Turner Nicholas C., Finn Richard S., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Palbociclib加上高龄妇女的内分泌治疗，具有人力资源+ / Her2晚期乳腺癌：对随机腭临床研究的汇总分析
2. Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 [J] . Nadia Harbeck, Marco Colleoni, Angela Demichele, The Breast : . 2017,第期

机译：Palbociclib（PAL）Pus Fulvestrant（F）对患有内分泌激素受体阳性（HR +）的地理区域，人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）的疗效和来自帕拉马的患者 - 3.
3. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR1/HER2-Advanced Breast Cancer [J] . Dieras Veronique, Rugo Hope S., Schnell Patrick, Journal of the National Cancer Institute . 2019,第4期

机译：Palbociclib的长期合并安全分析与HR1 / HER2晚期乳腺癌内分泌治疗组合
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Adherence to Adjuvant Endocrine Therapy among Women Diagnosed with Early Breast Cancer. [D] . Farias, Albert. 2015

机译：在诊断为早期乳腺癌的女性中坚持辅助内分泌治疗。
6. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer [O] . Véronique Diéras, Hope S Rugo, Patrick Schnell, -1

机译：Palbociclib联合内分泌治疗HR + / HER2-晚期乳腺癌的长期综合安全性分析
7. Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials [O] . V. Rossi, D. Giannarelli, P. Berchialla, 2018

机译：根据不同的预后亚组和事实试验

Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

摘要

著录项

相似文献

相关主题

期刊订阅